Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPTLC1 | O15269 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.31 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17868585 | 0.87 | SPTLC1 (0.33) | SPTLC1CREBBP | |
| SCHEMBL17868657 | 0.84 | MTHFD2 (0.34) | SPTLC1CREBBPMTHFD2BRD4 | |
| SCHEMBL17868683 | 0.80 | MTHFD2 (0.31) | MTHFD2 | |
| SCHEMBL17870542 | 0.78 | MTHFD2 (0.30) | CREBBPMTHFD2BRD4 | |
| SCHEMBL17868675 | 0.78 | MTHFD2 (0.30) | MTHFD2 | |
| SCHEMBL17868666 | 0.78 | CREBBP (0.33) | CREBBPCNR2BRD4 | |
| SCHEMBL20525248 | 0.77 | CREBBP (0.32) | SPTLC1CREBBPMTHFD2BRD4 | |
| SCHEMBL17870546 | 0.77 | BRD4 (0.30) | CREBBPBRD4 | |
| SCHEMBL17868725 | 0.77 | CREBBP (0.32) | SPTLC1CREBBPBRD4 | |
| SCHEMBL17868624 | 0.76 | RORC (0.31) | CREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544141-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190077800-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-10093669-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9518057-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077800-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | SPTLC1 3466/4885CREBBP 134/4885MTHFD2 2465/4885 |
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | SPTLC1 3466/4885CREBBP 134/4885MTHFD2 2465/4885 |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | SPTLC1 3466/4885CREBBP 134/4885MTHFD2 2465/4885 |
| US-10544141-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | SPTLC1 3466/4885CREBBP 134/4885MTHFD2 2465/4885 |
| US-10093669-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | SPTLC1 3466/4885CREBBP 134/4885MTHFD2 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.